 |
|
|
| |
Patient-reported outcome (PRO) measures at 12 months in a real-world cohort of people living with HIV with a high prevalence of comorbidities receiving bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Europe, Canada, and Israel
|
| |
| |
EACS 2021 Oct 27-30
Jason Brunetta,1 Antonella D'Arminio Monforte,2 Daniel Elbirt,3 Nils Postel,4 Berend van Welzen,5 Jérémy Zeggagh,6 Ana Milinkovic,7 Andrea Marongiu,8 Marion Heinzkill,9 David Thorpe,8 Almudena Torres Cornejo,10 Antonio Antela11
1Maple Leaf Medical Clinic, Toronto, Ontario, Canada; 2ASST Santi Paolo e Carlo, San Paolo Hospital, University of Milan, Milan, Italy; 3Kaplan Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; 4Prinzmed Medical Practice, Munich, Germany; 5University Medical Center Utrecht, Utrecht, Netherlands; 6Hôpital Saint-Louis AP-HP, Paris, France; 7Chelsea and Westminster Hospital, London, UK; 8Gilead Sciences Europe Ltd, Stockley Park, UK; 9Gilead Sciences GmbH, Martinsried, Germany; 10Gilead Sciences, Amsterdam, Netherlands; 11Hospital Clínico Universitario de Santiago de Compostela, A Coruña, Spain
|
| |
|
|
|
|
|
